Hematological Complications After Renal Transplantation
Özet
Hematologic complications after renal transplantation are significant clinical issues that can occur in both the early and late post-transplant periods and directly affect patient prognosis. The most common of these complications include anemia, leukopenia, and thrombocytopenia; and their etiology involves surgical blood loss, graft dysfunction, immunosuppressive medications, infections, and nutritional deficiencies. Additionally, more specific conditions such as post-transplant erythrocytosis, post-transplant lymphoproliferative disease, and thrombotic microangiopathy may also be observed. Management focuses on addressing the underlying cause and includes modification of immunosuppression, treatment of infections, and targeted therapies when necessary. This section discusses the pathogenesis, diagnostic approach, and current treatment strategies for hematologic complications that develop after renal transplantation.
Referanslar
Zucker K, Tsaroucha A, Olson L, et al. Evidence that tacrolimus augments the bioavailability of mycophenolate mofetil through the inhibition of mycophenolic acid glucuronidation. Ther Drug Monit. 1999;21(1):35-43.
Webster AC, Lee VW, Chapman JR, et al. Target of rapamycin inhibitors (TOR-I; sirolimus and everolimus) for primary immunosuppression in kidney transplant recipients. Cochrane Database Syst Rev. 2006;(2):CD004290.
Dale LA, Freed JA. Hematologic Considerations in Kidney Transplantation: Core Curriculum 2025. Am J Kidney Dis. 2025;86(6):828-842.
Kidney Disease: Improving Global Outcomes (KDIGO) Transplant Work Group. KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant. 2009;9 Suppl 3:S1-155.
Reindl-Schwaighofer R, Oberbauer R. Blood disorders after kidney transplantation. Transplant Rev (Orlando). 2014;28(2):63-75.
Mix TC, Kazmi W, Khan S, et al. Anemia: a continuing problem following kidney transplantation. Am J Transplant. 2003;3(11):1426-33.
Vanrenterghem Y. Anaemia after renal transplantation. Nephrol Dial Transplant. 2004;19 Suppl 5:V54-58.
Massicotte-Azarniouch D, Sood MM, Fergusson DA, et al. Blood Transfusion and Adverse Graft-related Events in Kidney Transplant Patients. Kidney Int Rep. 2021;6(4):1041-1049.
Vlahakos DV, Marathias KP, Agroyannis B, et al. Posttransplant erythrocytosis. Kidney
Int. 2003;63(4):1187-94.
Vlahakos DV, Marathias KP, Madias NE. The role of the renin-angiotensin system in the
regulation of erythropoiesis. Am J Kidney Dis. 2010;56(3):558-65.
Afrouzian M, Kozakowski N, Liapis H, et al.Thrombotic Microangiopathy in the Renal Allograft: Results of the TMA Banff Working Group Consensus on Pathologic Diagnostic Criteria. Transpl Int. 2023;36:11590.
Hanto DW. Classification of Epstein-Barr virus-associated posttransplant lymphoproliferative diseases: implications for understanding their pathogenesis and developing rational treatment strategies. Annu Rev Med. 1995;46:381-94.
Achkar R, Chiba AK, Zampieri-Filho JP, et al. Hemolytic anemia after kidney transplantation: a prospective analysis. Transfusion 2011;51:2495-9.
Henter JI. Hemophagocytic Lymphohistiocytosis. N Engl J Med. 2025;392(6):584-598.
